Presentation Authors: Osamu Soma*, Shingo Hatakeyama, Tohru Yoneyama, Daisuke Noro, Yuki Tobisawa, Yasuhiro Hashimoto, Hirosaki, Japan, Takuya Koie, Gifu, Japan, Shin-Ichiro Nishimura, Sapporo, Japan, Hideo Sasaki, Kawasaki, Japan, Mitsuru Saito, Akita, Japan, Hiroshi Harada, Sapporo, Japan, Tatsuya Chikaraishi, Kawasaki, Japan, Hideki Ishida, Kazunari Tanabe, Tokyo, Japan, Shigeru Satoh, Akita, Japan, Chikara Ohyama, Hirosaki, Japan
Introduction: We examined whether serum N-glycan profile can be used as a diagnostic marker of graft rejection after living-donor kidney transplants (KT).
Methods: A total 197 KT recipients were retrospectively examined. N-glycan levels were analyzed in postoperative serum samples using glycoblotting combined with mass spectrometry. Multivariate discriminant analysis was performed to predict graft rejection based on a combination of age, gender, immunological risk factors, and serum N-glycan levels at post-KT day 1, 7, and 28, and an N-glycan score was created. Then, we developed N-glycan summary score (sum of day 1, 7, and 28) to access the impact of longitudinal measurement of serum N-glycan profile on graft rejection.
Results: Of the 197 patients, longitudinal serum samples were available from 174 cases. Of those, 52 showed graft rejection and 122 recipients did not show graft rejection. N-glycan scores were significantly higher in the patients with graft rejection than those without. N-glycan summary score >0.604 identified graft rejection with 90% sensitivity and 75% specificity; with an Area-under-curve value of 0.89. Recipients with higher N-glycan summary score (â‰¥0) had significantly shorter rejection-free survival than those with lower scores ( < 0).
Conclusions: Our data suggest that longitudinal serum N-glycan evaluation can help predict graft rejection.